Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Sees New MOAs For Refractory Populations As Anti-Depressant For Neuro Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J’s five key therapeutic areas appear to be operating on all cylinders, based on presentations at the company’s annual analyst meeting. In neuroscience, already one of its core fields, it is expanding its anti-psychotic and mood disorders franchise to focus on difficult-to-treat patients, as well re-doubling efforts in challenging diseases like Alzheimer’s disease.

Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel